137 lines
85 KiB
Text
137 lines
85 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK453041">
|
|
<meta name="ncbi_domain" content="glyco3">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK453041/?report=reader">
|
|
<meta name="ncbi_pagename" content="Genetic Disorders of Glycosylation - Essentials of Glycobiology - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Genetic Disorders of Glycosylation - Essentials of Glycobiology - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/glyco3/ch44/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/glyco3/ch46/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/glyco3/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="citation_inbook_title" content="Essentials of Glycobiology [Internet]. 3rd edition">
|
|
<meta name="citation_title" content="Genetic Disorders of Glycosylation">
|
|
<meta name="citation_publisher" content="Cold Spring Harbor Laboratory Press">
|
|
<meta name="citation_date" content="2017">
|
|
<meta name="citation_author" content="Hudson H. Freeze">
|
|
<meta name="citation_author" content="Harry Schachter">
|
|
<meta name="citation_author" content="Taroh Kinoshita">
|
|
<meta name="citation_pmid" content="28876812">
|
|
<meta name="citation_doi" content="10.1101/glycobiology.3e.045">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK453041/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Genetic Disorders of Glycosylation">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="Cold Spring Harbor Laboratory Press">
|
|
<meta name="DC.Contributor" content="Hudson H. Freeze">
|
|
<meta name="DC.Contributor" content="Harry Schachter">
|
|
<meta name="DC.Contributor" content="Taroh Kinoshita">
|
|
<meta name="DC.Date" content="2017">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK453041/">
|
|
<meta name="DC.Language" content="en">
|
|
<meta name="description" content="This chapter discusses inherited human diseases that affect glycan biosynthesis and metabolism. Representative examples of diseases caused by defects in several major glycan families are described. Disorders affecting the degradation of glycans are described in Chapter 44.">
|
|
<meta name="og:title" content="Genetic Disorders of Glycosylation">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="This chapter discusses inherited human diseases that affect glycan biosynthesis and metabolism. Representative examples of diseases caused by defects in several major glycan families are described. Disorders affecting the degradation of glycans are described in Chapter 44.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK453041/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-glyco3-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/glyco3/ch45/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK579928/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8D71F77D6856610000000000F000C7.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK453041/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/glyco3/ch44/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Chapter 45, Genetic Disorders of Glycosylation</div><div class="j">Essentials of Glycobiology [Internet]. 3rd edition</div></div><div class="tail"><a href="/books/n/glyco3/ch46/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK453041/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK453041/&text=Genetic%20Disorders%20of%20Glycosylation"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/glyco3/?report=reader">Title Information</a><a href="/books/n/glyco3/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK453041/?report=classic">Switch to classic view</a><a href="/books/NBK453041/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK453041%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8D71F77D6856610000000000F000C7.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><p class="vip-notice"><strong><a href="/books/n/glyco4/?report=reader">A new version of this title is available</a></strong></p><p class="vip-notice"><strong><a href="/books/NBK579928/?report=reader">See the updated version of this chapter</a></strong></p><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK453041_"><span class="label">Chapter 45</span><span class="title" itemprop="name">Genetic Disorders of Glycosylation</span></h1><p class="contribs">Freeze HH, Schachter H, Kinoshita T.</p><p class="fm-aai"><a href="#_NBK453041_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="_abs_rndgid_" itemprop="description"><p>This chapter discusses inherited human diseases that affect glycan biosynthesis and metabolism. Representative examples of diseases caused by defects in several major glycan families are described. Disorders affecting the degradation of glycans are described in <a href="/books/n/glyco3/ch44/?report=reader">Chapter 44</a>.</p></div><div id="Ch45_s1"><h2 id="_Ch45_s1_">INHERITED PATHOLOGICAL MUTATIONS OCCUR IN ALL MAJOR GLYCAN FAMILIES</h2><p>Nearly all inherited disorders in glycan biosynthesis were discovered in the last 20 years. They are rare, biochemically and clinically heterogeneous, and usually affect multiple organ systems. Some defects strike only a single glycosylation pathway, whereas others impact several. Defects occur in (1) the activation, presentation, and transport of sugar precursors; (2) glycosidases and glycosyltransferases; and (3) proteins that traffic glycosylation machinery or maintain Golgi homeostasis. A few disorders can be treated by the consumption of monosacccharides. The rapid growth in the number of these discovered disorders is shown in <a class="figpopup" href="/books/NBK453041/figure/ch45.f1/?report=objectonly" target="object" rid-figpopup="figch45f1" rid-ob="figobch45f1">Figure 45.1</a>.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figch45f1" co-legend-rid="figlgndch45f1"><a href="/books/NBK453041/figure/ch45.f1/?report=objectonly" target="object" title="FIGURE 45.1." class="img_link icnblk_img figpopup" rid-figpopup="figch45f1" rid-ob="figobch45f1"><img class="small-thumb" src="/books/NBK453041/bin/ch45f01.gif" src-large="/books/NBK453041/bin/ch45f01.jpg" alt="FIGURE 45.1.. Glycosylation-related disorders." /></a><div class="icnblk_cntnt" id="figlgndch45f1"><h4 id="ch45.f1"><a href="/books/NBK453041/figure/ch45.f1/?report=objectonly" target="object" rid-ob="figobch45f1">FIGURE 45.1.</a></h4><p class="float-caption no_bottom_margin">Glycosylation-related disorders. The graph shows the cumulative number of human glycosylation disorders in various biosynthetic pathways and the year of their identification. In most cases, the year indicates the definitive proof of gene and specific <a href="/books/NBK453041/figure/ch45.f1/?report=objectonly" target="object" rid-ob="figobch45f1">(more...)</a></p></div></div><p>Selected disorders are listed in <a class="figpopup" href="/books/NBK453041/table/CH45TB1/?report=objectonly" target="object" rid-figpopup="figCH45TB1" rid-ob="figobCH45TB1">Table 45.1</a> and all known disorders in <a href="/books/n/glyco3/app_glycosylation_disorder/?report=reader">Online Appendix 45A</a>. Disease nomenclature has evolved. Congenital disorders of glycosylation (CDG) were originally defined as genetic defects in N-glycosylation, but now the term is applied to any glycosylation defect, by indicating the mutated gene followed by “-CDG” suffix (e.g., PMM2-CDG). CDGs are rare primarily because embryos with complete defects in a step of glycosylation do not usually survive to be born, documenting the critical biological roles of glycans in humans. CDG patients that survive are usually hypomorphic, retaining at least some activity of the pathways involved.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figCH45TB1"><a href="/books/NBK453041/table/CH45TB1/?report=objectonly" target="object" title="TABLE 45.1." class="img_link icnblk_img figpopup" rid-figpopup="figCH45TB1" rid-ob="figobCH45TB1"><img class="small-thumb" src="/books/NBK453041/table/CH45TB1/?report=thumb" src-large="/books/NBK453041/table/CH45TB1/?report=previmg" alt="TABLE 45.1." /></a><div class="icnblk_cntnt"><h4 id="CH45TB1"><a href="/books/NBK453041/table/CH45TB1/?report=objectonly" target="object" rid-ob="figobCH45TB1">TABLE 45.1.</a></h4><p class="float-caption no_bottom_margin">Selected genetic defects of glycans in humans </p></div></div></div><div id="Ch45_s2"><h2 id="_Ch45_s2_">DEFECTS IN N-GLYCAN BIOSYNTHESIS</h2><div id="Ch45_s2a"><h3>Clinical and Laboratory Features and Diagnosis</h3><p>The broad clinical features of disorders in which N-glycan biosynthesis is defective involve many organ systems, but are especially common in the central and peripheral nervous systems, hepatic, visual, and immune systems. The generality and variability of clinical features makes it difficult for physicians to recognize CDG patients. The first were identified in the early 1980s based primarily on deficiencies in multiple plasma glycoproteins. The patients were also delayed in reaching growth and developmental milestones and had low muscle tone, incomplete brain development, visual problems, coagulation defects, and endocrine abnormalities. However, many of these symptoms are seen in patients with other inherited multisystemic metabolic disorders, such as mitochondria-based diseases. CDG patients can be distinguished because they often have abnormal glycosylation of common liver-derived serum proteins containing disialylated, biantennary N-glycans. Serum transferrin is especially convenient because it has two N-glycosylation sites each containing disialylated biantennary N-glycans. Different glycoforms can be resolved by isoelectric focusing (IEF) or ion-exchange chromatography, but better accuracy and sensitivity is achieved by mass spectrometry (MS) of purified transferrin. This simple litmus test alerts physicians to likely CDG patients without knowing the gene or molecular basis of the disease.</p><p>CDG defects may be divided into two types based on transferrin glycoforms. Type I (CDG-I) patients lack one or both N-glycans because of defects in the biosynthesis of the lipid-linked oligosaccharide (LLO) and its transfer to proteins. Type II (CDG-II) patients have incomplete protein-bound glycans because of abnormal processing. These differences were used to name the disorders (e.g., CDG-Ia and CDG-IIa), which oriented the search for a defective gene. This system is gradually being replaced by the affected gene name with a CDG suffix, such as PMM2-CDG. The biosynthetic pathways and locations of N-glycan defects are shown in <a class="figpopup" href="/books/NBK453041/figure/ch45.f2/?report=objectonly" target="object" rid-figpopup="figch45f2" rid-ob="figobch45f2">Figure 45.2</a>.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figch45f2" co-legend-rid="figlgndch45f2"><a href="/books/NBK453041/figure/ch45.f2/?report=objectonly" target="object" title="FIGURE 45.2." class="img_link icnblk_img figpopup" rid-figpopup="figch45f2" rid-ob="figobch45f2"><img class="small-thumb" src="/books/NBK453041/bin/ch45f02.gif" src-large="/books/NBK453041/bin/ch45f02.jpg" alt="FIGURE 45.2.. Congenital disorders of glycosylation in the N-glycosylation pathway." /></a><div class="icnblk_cntnt" id="figlgndch45f2"><h4 id="ch45.f2"><a href="/books/NBK453041/figure/ch45.f2/?report=objectonly" target="object" rid-ob="figobch45f2">FIGURE 45.2.</a></h4><p class="float-caption no_bottom_margin">Congenital disorders of glycosylation in the N-glycosylation pathway. The figure shows individual steps in lipid-linked oligosaccharide (LLO) biosynthesis, glycan transfer to protein, and N-glycan processing similar to Figure 9.3 and Figure 9.4. The shuttling <a href="/books/NBK453041/figure/ch45.f2/?report=objectonly" target="object" rid-ob="figobch45f2">(more...)</a></p></div></div></div><div id="Ch45_s2b"><h3>Type I Congenital Disorders of Glycosylation</h3><p>A complete absence of N-glycans is lethal. Therefore, known mutations generate hypomorphic alleles, not complete knockouts. A deficiency in any of the steps required for the assembly of LLO in the endoplasmic reticulum (ER) (e.g., nucleotide sugar synthesis or sugar addition catalyzed by a glycosyltransferase) (<a href="/books/n/glyco3/ch9/?report=reader">Chapter 9</a>) produces a structurally incomplete LLO. Because the oligosaccharyltransferase prefers full-sized LLO glycans, this results in hypoglycosylation of multiple glycoproteins. This means that some N-glycan sites are not modified. Importantly, many deficiencies in LLO synthesis produce incomplete LLO intermediates. Most of the LLO assembly steps are not easy to assay, but LLO assembly is conserved from yeast to humans, and intermediates that accumulate in CDG patients often correspond to the intermediates seen in mutant <i>Saccharomyces cerevisiae</i> strains with known defects in LLO assembly. Some mutant mammalian cells (e.g., Chinese hamster ovary cells) have been shown to have similar defects (<a href="/books/n/glyco3/ch49/?report=reader">Chapter 49</a>). The close homology between yeast and human genes enables the normal human orthologs to rescue defective glycosylation in mutant yeast strains, whereas mutant orthologs from patients do not. This provides substantial clues to the likely human defect, along with a system in which to perform functional assays.</p><p>PMM2-CDG (CDG-Ia) in <a class="figpopup" href="/books/NBK453041/table/CH45TB1/?report=objectonly" target="object" rid-figpopup="figCH45TB1" rid-ob="figobCH45TB1">Table 45.1</a> is the most common CDG with more than 800 cases identified worldwide. The patients have moderate to severe developmental and motor deficits, hypotonia, dysmorphic features, failure to thrive, liver dysfunction, coagulopathy, and abnormal endocrine functions. More than 100 mutations found in <i>phosphomannomutase 2</i> (<i>PMM2</i>) impair conversion of Man-6-P to Man-1-P, which is a precursor required for the synthesis of GDP-mannose (GDP-Man) and dolichol-P-mannose (Dol-P-Man). Both donors are substrates for the mannosyltransferases involved in the synthesis of Glc<sub>3</sub>Man<sub>9</sub>GlcNAc<sub>2</sub>-P-P-Dol and its level is decreased in cells from PMM2-CDG patients. Patients have hypomorphic alleles because complete loss of PMM2 function is lethal. Mouse embryos lacking <i>Pmm2</i> die 2–4 days after fertilization, whereas some of those with hypomorphic alleles survive. There are currently no therapeutic options for PMM2-CDG patients.</p><p>MPI-CDG (CDG-Ib) in <a class="figpopup" href="/books/NBK453041/table/CH45TB1/?report=objectonly" target="object" rid-figpopup="figCH45TB1" rid-ob="figobCH45TB1">Table 45.1</a> is caused by mutations in <i>MPI</i> (<i>mannose-6-phosphate isomerase</i>). This enzyme interconverts fructose-6-P and mannose-6-P (Man-6-P). In contrast to PMM2-CDG, these patients do not have intellectual disability or developmental abnormalities. Instead, they have impaired growth, hypoglycemia, coagulopathy, severe vomiting and diarrhea, protein-losing enteropathy, and hepatic fibrosis. Several patients died of severe bleeding before the basis of this CDG was known. Mannose dietary supplements effectively treat these patients. Man-6-P can be generated directly by hexokinase-catalyzed phosphorylation of mannose (<a href="/books/n/glyco3/ch5/?report=reader">Chapter 5</a>). This pathway is intact in MPI-CDG patients. Human plasma contains ∼50 µ<span class="small-caps">m</span> mannose because of export following glycan degradation and processing. Mannose supplements correct coagulopathy, hypoglycemia, protein-losing enteropathy, and intermittent gastrointestinal problems, as well as normalize the glycosylation of plasma transferrin and other serum glycoproteins. Because orally administered mannose is well tolerated, this approach is clearly a satisfyingly effective, although not curative, therapy for this life-threatening condition.</p><p>Complete loss of the <i>Mpi</i> gene in mice is lethal at about embryonic day 11.5. N-Glycosylation is normal, but death results from accumulation of intracellular Man-6-P, which depletes ATP and inhibits several glycolytic enzymes. Providing dams with extra mannose during pregnancy only hastens the embryo's demise via the “honeybee effect,” which occurs when bees are given only mannose instead of glucose. The bees continue flying for a short time and then literally drop dead. They have low MPI activity compared with hexokinase and therefore accumulate Man-6-P, which they degrade, and perhaps rephosphorylate, further depleting ATP. Even more serious is that Man-6-P inhibits several glycolytic enzymes. Entry of Man-6-P into glycolysis is very slow and thus the bees become energy-starved and die within a few minutes. MPI-CDG patients have sufficient residual MPI activity and do not accumulate intracellular Man-6-P when given mannose, although the amount is sufficient to correct impaired glycosylation. However, the honeybee effect may be at play again in <i>Mpi</i>-hypomorphic mice because dams given modest amounts of mannose during pregnancy produce pups with no lenses. The effect is quite specific to lens development in which the MPI activity is very low even in normal mice. A hypomorphic mutation and increased substrate load combines so that Man-6-P accumulates.</p><p>Other types of CDG-I have a broad range of clinical phenotypes including low LDL, low IgG, kidney failure, genital hypoplasia, and cerebellar hypoplasia. The reasons for these effects are unknown. Patients with mutations in nearly all the remaining steps of LLO biogenesis have been found (<a class="figpopup" href="/books/NBK453041/table/CH45TB1/?report=objectonly" target="object" rid-figpopup="figCH45TB1" rid-ob="figobCH45TB1">Table 45.1</a>; <a href="/books/n/glyco3/app_glycosylation_disorder/?report=reader">Online Appendix 45A</a>; <a class="figpopup" href="/books/NBK453041/figure/ch45.f1/?report=objectonly" target="object" rid-figpopup="figch45f1" rid-ob="figobch45f1">Figure 45.1</a>) including defects in dolichol biosynthesis (<i>cis</i>-isoprenyl transferase, dolichol-kinase, and polyprenol reductase) and in a putative LLO flippase. Mutations in five of the oligosaccharyltransferase subunits also cause a CDG.</p></div><div id="Ch45_s2c"><h3>Type II Congenital Disorders of Glycosylation</h3><p>CDG-II disorders (<a class="figpopup" href="/books/NBK453041/figure/ch45.f2/?report=objectonly" target="object" rid-figpopup="figch45f2" rid-ob="figobch45f2">Figure 45.2</a>) affect N-glycan processing and include defects in glycosyltransferases, nucleotide sugar transporters, vacuolar pH regulators, and multiple cytoplasmic proteins that traffic glycosylation machinery within the cell and maintain Golgi homeostasis.</p><p>In B4GALT1-CDG, glycans showed the loss of both galactose (Gal) and sialic acid (Sia) from transferrin because of loss of β1-4 galactosyltransferase I activity. A similar glycan pattern occurs in the X-linked SLC35A2-CDG, because of loss of UDP-Gal transporter activity. Surprisingly, within a few years after birth, abnormal glycosylation becomes normal. This is probably due to somatic mosaicism of cells carrying the mutated <i>SLC35A2</i> gene and unaffected cells and selection against the affected cells.</p><p>Patients with leukocyte adhesion deficiency type II (LAD-II or SLC35C1-CDG) were found to have mutations in <i>SLC35C1</i>, encoding a GDP-Fucose (Fuc) transporter. Here, transferrin sialylation was normal, so this defect was not detected by the usual test, but some serum proteins and O-linked glycans on leukocyte surface proteins were deficient in Fuc. One leukocyte protein carries a selectin ligand glycan, sialyl Lewis x, that mediates leukocyte rolling before extravasation of leukocytes from capillaries into tissues (<a href="/books/n/glyco3/ch34/?report=reader">Chapter 34</a>). This defect greatly elevates circulating leukocytes and decreases leukocyte extravasation so patients have frequent infections. A few patients responded to dietary Fuc therapy. Sialyl Lewis x reappeared on their leukocytes, and circulating neutrophils promptly returned to normal levels. Fuc is converted into Fuc-1-P by fucose kinase and then to GDP-Fuc by GDP-Fuc pyrophosphorylase (<a href="/books/n/glyco3/ch5/?report=reader">Chapter 5</a>). Fuc supplements must increase the amount of GDP-Fuc enough to correct the defect. A mouse model of Fuc deficiency lacks de novo biosynthesis of GDP-Fuc from GDP-Man (<a href="/books/n/glyco3/ch5/?report=reader">Chapter 5</a>). The mice die without Fuc supplements, but providing Fuc in the drinking water rapidly normalizes their elevated neutrophils. The treatment also corrects abnormal hematopoeisis resulting from disrupted O-Fuc-dependent Notch signaling.</p><p>CDG-II defects are also caused by mutations in the eight-subunit conserved oligomeric Golgi (COG) complex, which has multiple roles in trafficking within the Golgi. COG7-CDG (<a class="figpopup" href="/books/NBK453041/table/CH45TB1/?report=objectonly" target="object" rid-figpopup="figCH45TB1" rid-ob="figobCH45TB1">Table 45.1</a>) was discovered first. Trafficking of multiple glycosyltransferases and nucleotide sugar transporters were disrupted in COG7-CDG. The mutation affects the synthesis of both N- and O-glycans and glycosaminoglycan (GAG) chains. Mutations have now been found in all COG subunits except COG3. Mammalian cells deficient in COG1, COG2, COG3, and COG5 also show various degrees of altered glycosylation. Various mutations in a vacuolar H<sup>+</sup>-ATPase subunit also disrupt multiple glycosylation pathways, presumably because of an increase in Golgi pH and concomitant decrease in glycosyltransferase activities.</p><p>Other genetic defects that impair N-glycan synthesis include I-cell disease, which results from the lack of Man-6-P on lysosomal enzyme N-glycans (<a href="/books/n/glyco3/ch33/?report=reader">Chapter 33</a>). An unusual disorder called HEMPAS (hereditary erythroblastic multinuclearity with positive acidified-serum test) leads to abnormal red cell shape and instability (hemolysis) due to mutations in <i>SEC23B,</i> another intracellular trafficking protein that produces abnormal red blood cell glycans in several pathways.</p><p>In an interesting twist, it is possible to have diseases caused by “excessive” glycosylation. For example, Marfan syndrome results from mutations in <i>fibrillin1</i> (<i>FBN1</i>) and one of these creates an N-glycosylation site that disrupts multimeric assembly of FBN1. This may not be an isolated case. A survey of nearly 600 known pathological mutations in proteins traveling the ER–Golgi pathway showed that 13% of them create novel glycosylation sites. This is far greater than predicted by random missense mutations and may mean that hyperglycosylation leads to a new class of CDGs.</p></div></div><div id="Ch45_s3"><h2 id="_Ch45_s3_">GALACTOSEMIA</h2><p>Galactosemia refers to mutations in three genes involved in Gal metabolism. In “classical galactosemia,” Gal-1-P uridyltransferase (GALT; <a class="figpopup" href="/books/NBK453041/figure/ch45.f3/?report=objectonly" target="object" rid-figpopup="figch45f3" rid-ob="figobch45f3">Figure 45.3</a>) is deficient. This results in excess Gal-1-P and decreased synthesis and availability of UDP-Gal. Defects in UDP-Gal-4′-epimerase (GALE; <a class="figpopup" href="/books/NBK453041/figure/ch45.f3/?report=objectonly" target="object" rid-figpopup="figch45f3" rid-ob="figobch45f3">Figure 45.3</a>) or galactokinase (GALK; <a class="figpopup" href="/books/NBK453041/figure/ch45.f3/?report=objectonly" target="object" rid-figpopup="figch45f3" rid-ob="figobch45f3">Figure 45.3</a>) also cause the disease, but they are more rare.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figch45f3" co-legend-rid="figlgndch45f3"><a href="/books/NBK453041/figure/ch45.f3/?report=objectonly" target="object" title="FIGURE 45.3." class="img_link icnblk_img figpopup" rid-figpopup="figch45f3" rid-ob="figobch45f3"><img class="small-thumb" src="/books/NBK453041/bin/ch45f03.gif" src-large="/books/NBK453041/bin/ch45f03.jpg" alt="FIGURE 45.3.. UDP-Gal synthesis and galactosemia." /></a><div class="icnblk_cntnt" id="figlgndch45f3"><h4 id="ch45.f3"><a href="/books/NBK453041/figure/ch45.f3/?report=objectonly" target="object" rid-ob="figobch45f3">FIGURE 45.3.</a></h4><p class="float-caption no_bottom_margin">UDP-Gal synthesis and galactosemia. The most common form of galactosemia is due to a deficiency of galactose-1-phosphate uridyltransferase (GALT). This enzyme normally uses Gal-1-P derived from dietary Gal. In the absence of GALT, Gal-1-P accumulates, <a href="/books/NBK453041/figure/ch45.f3/?report=objectonly" target="object" rid-ob="figobch45f3">(more...)</a></p></div></div><p>GALT-deficient infants fail to thrive and have enlarged liver, jaundice, and cataracts. A lactose-free diet ameliorates most of the acute symptoms by reducing the amount of Gal entering the pathway and the accumulation of Gal and Gal-1-P. Reducing Gal decreases galactitol and galactonate, which are produced via reductive or oxidative metabolism of Gal, respectively. Galactitol is not metabolized further and has osmotic properties that contribute to cataract formation. Unfortunately, a Gal-free diet apparently does not prevent the appearance of cognitive disability, ataxia, growth retardation, and ovarian dysfunction that are characteristic of this disease. The long-term complications in treated GALT-deficient individuals may be due to small amounts of toxic metabolites that accumulate. Alternatively, the complications may reflect dysfunctions that originated during fetal life. GALT deficiency may decrease UDP-Gal and galactosylated glycans. Hypogalactosylation of glycoproteins and glycolipids has been observed in some GALT-deficient individuals. But, in addition to loss of Gal on glycans, some patients who mistakenly receive Gal also synthesize transferrin that is missing both N-glycans. The basis of the combined absence of Gal/Sia and entire N-glycans is not understood, but the pattern returns to normal when the patients are placed on a Gal-free diet.</p></div><div id="Ch45_s4"><h2 id="_Ch45_s4_">MUSCULAR DYSTROPHIES</h2><div id="Ch45_s4a"><h3>Congenital Muscular Dystrophies</h3><p>Mutations altering O-Man glycans (<a href="/books/n/glyco3/ch13/?report=reader">Chapter 13</a>), primarily on α-dystroglycan (α-DG) cause at least 16 types of congenital muscular dystrophy (CMD) termed dystroglycanopathies (<a class="figpopup" href="/books/NBK453041/figure/ch45.f4/?report=objectonly" target="object" rid-figpopup="figch45f4" rid-ob="figobch45f4">Figure 45.4</a>). α-DG at neuromuscular junctions links skeletal muscle cell cytoskeleton to laminin in the extracellular matrix. The clinical spectrum of dystroglycanopathies is broad, ranging from very severe, and often lethal, musculo-oculo-encephalopathies, such as Walker–Warburg syndrome (WWS), muscle–eye–brain disease (MEB), and Fukuyama congenital muscular dystrophy (FCMD) to milder forms of limb-girdle muscular dystrophy. Genetic analysis of these disorders has been indispensable for discovering functional glycans and their biosynthesis. The complex pathway is presented in <a class="figpopup" href="/books/NBK453041/figure/ch45.f4/?report=objectonly" target="object" rid-figpopup="figch45f4" rid-ob="figobch45f4">Figure 45.4</a> and <a href="/books/n/glyco3/ch13/?report=reader">Chapter 13</a>. The pathway is initiated in the ER by the transfer of Man to Ser/Thr via the protein O-mannosyltransferase complex containing POMT1 and POMT2 (<a class="figpopup" href="/books/NBK453041/table/CH45TB1/?report=objectonly" target="object" rid-figpopup="figCH45TB1" rid-ob="figobCH45TB1">Table 45.1</a>). In the Golgi, this pathway generates more than 20 O-Man glycans in mammals. An unusual feature on one subset of O-Man glycans is the existence of a Man-6-P generated by POMK. The Man-6-P containing CoreM3 glycan consists of Man-6-P, GlcNAc (transferred by POMGNT2), and GalNAc (transferred by B3GALNT2). The trisaccharide core is extended by two units of ribitol-5-phosphate and a single repeat of xylose (Xyl) and glucuronic acid (GlcA). This structure is elongated by an alternating disaccharide (β1-3Xylα1-3GlcA). Two ribitol-5-phosphates are sequentially transferred by FKTN (fukutin) and FKRP (fukutin-related protein) from CDP-ribitol, which is generated by ISPD. Xyl and GlcA in the single repeat are transferred by TMEM5 and B4GAT1, respectively. The elongation by the alternating disaccharide is catalyzed by LARGE<i>.</i> The polymeric glycan (matriglycan) is recognized by several diagnostic monoclonal antibodies and is necessary for the binding of laminin and other molecules to α-DG.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figch45f4" co-legend-rid="figlgndch45f4"><a href="/books/NBK453041/figure/ch45.f4/?report=objectonly" target="object" title="FIGURE 45.4." class="img_link icnblk_img figpopup" rid-figpopup="figch45f4" rid-ob="figobch45f4"><img class="small-thumb" src="/books/NBK453041/bin/ch45f04.gif" src-large="/books/NBK453041/bin/ch45f04.jpg" alt="FIGURE 45.4.. O-Man glycan biosynthetic pathway." /></a><div class="icnblk_cntnt" id="figlgndch45f4"><h4 id="ch45.f4"><a href="/books/NBK453041/figure/ch45.f4/?report=objectonly" target="object" rid-ob="figobch45f4">FIGURE 45.4.</a></h4><p class="float-caption no_bottom_margin">O-Man glycan biosynthetic pathway. The biosynthetic pathways of representative O-Man glycans are shown. Genes that cause a disorder are indicated in red. Three main groups are identified: core M1–M3. All O-Man glycans are initiated on either a <a href="/books/NBK453041/figure/ch45.f4/?report=objectonly" target="object" rid-ob="figobch45f4">(more...)</a></p></div></div><p>O-Man glycans can also play a traitorous role, because they are receptor molecules for Lassa Virus entry into cells. This feature was cleverly exploited to screen libraries and identify genes required for virus entry. The method correctly identified all previously known WWS-causing genes and predicted new culprits. So far, sixteen genes have been proven to cause a Dystroglycanopathy (<i>POMT1, POMT2, POMGNT1, FKTN, FKRP, ISPD, LARGE, POMGNT2, TMEM5, B3GALNT2, POMK, B4GAT1, GMPPB, DPM1, DPM2,</i> and <i>DPM3</i>) of which three (<i>DPM1–3</i>) are required for N-glycan and glycosylphosphatidylinositol (GPI)-anchor biosynthesis.</p><p>Although α-DG is the major carrier of LARGE-modified O-Man glycans, cadherins carry O-Man glycans important for their roles in cell–cell adhesion. Clustered protocadherins that contain O-Man glycans are regulated during brain development and form larger oligomers. The O-Man glycans seem to orient cadherin domains for critical interactions. O-Man in clustered protocadherins may help explain ocular and brain malformations in disorders such as WWS.</p><p>Clinical criteria previously defined the Dystroglycanopathies, but now they are defined by the mutated gene as mutations in genes of the pathway fit the clinical criteria. WWS is the most severe CMD. Patients live about one year and have multiple brain abnormalities, and severe muscular dystrophy. About 20% of patients have mutations in <i>POMT1</i> and a few have mutations in <i>POMT2</i>. Others have defects in <i>FKTN</i> and <i>FKRP</i>, but mutations in both also cause milder forms of muscular dystrophy.</p><p><i>POMGNT1</i> is mutated in MEB, which is characterized by symptoms similar to, but milder than, WWS. The most severely affected MEB patients die during the first years of life, but the majority of mild cases survive to adulthood. Fukuyama muscular dystrophy (FCMD) is caused by a single 3-kb 3′-retrotransposon insertional event into the <i>FKTN</i> gene, which occurred 2000–2500 years ago. This partially reduces the stability of the mRNA, making it a relatively mild mutation. FCMD is one of the most common types of CMD in Japan with a carrier frequency of 1/188. <i>Fktn</i>-null mice die by E9.5 in embryogenesis and appear to have basement membrane defects. Congenital muscular dystrophy type 1C (MDC1C) is a relatively mild disorder that is caused by mutations in <i>FKRP</i>. Patients with MDC1D, a limb-girdle muscular dystrophy, contain mutations in <i>LARGE</i>, originally described in myodystrophic mice (<i>myd;</i> now called <i>Large</i><sup><i>myd</i></sup>). The protein has two glycosyltransferase signatures (DXD) in different domains that account for xylosyl- and glucuronosyl-transferase actitivities respectively (<a href="/books/n/glyco3/ch13/?report=reader">Chapter 13</a>).</p></div><div id="Ch45_s4b"><h3>GNE Myopathy</h3><p>Recessive mutations in <i>GNE</i> cause adult-onset GNE myopathy (previously named hereditary inclusion body myopathy type 2 (HIBM2 or Nonaka myopathy) (<a class="figpopup" href="/books/NBK453041/table/CH45TB1/?report=objectonly" target="object" rid-figpopup="figCH45TB1" rid-ob="figobCH45TB1">Table 45.1</a>). It occurs worldwide, but one mutation (p.Met745Thr) is especially common among Persian Jews (1:1500) and occurs in the kinase domain (<a href="/books/n/glyco3/ch5/?report=reader">Chapter 5</a>). GNE mutations occur in various combinations in both GNE enzymatic domains, and variably affect enzyme activity. The mutations moderately reduce enzymatic activity and reduce sialylation in mouse models. Sia is efficiently salvaged from degraded glycoproteins, but there is little information on the cell-type preference or age-dependent contributions of the de novo versus salvage pathways. <i>Gne</i>-null mice die during embryogenesis and most mice homozygous for the knockin p.Met743Thr mutation die a few days after birth because of severe hematuria and proteinuria, not myopathy. Glomerular abnormalities in the podocyte basement membrane result from undersialylated in foot podocytes such as podocalyxin and nephrin. Providing <i>N</i>-acetylmannosamine (ManNAc) to the pups in the neonatal period rescues some of them and increases sialylation of podocalyxin and nephrin. Mutant p.Met743Thr survivors who did not receive ManNAc after the neonatal period develop adult-onset hyposialylation of muscle tissue, which can be rescued by oral ManNAc therapy at adult age. Oral ManNAc is being tested as a therapy for GNE myopathy patients, as well as for patients with primary glomerular diseases (focal segmental glomerulosclerosis, minimal change disease, and membranous nephropathy).</p><p>Another mouse model, carrying a transgenic <i>Gne</i> mutation (p.Asp207Val) common in the Japanese population, develops a pathological adult-onset muscle phenotype involving β-amyloid deposition that precedes the accumulation of inclusion bodies. Providing modest amounts of Sia, <i>N</i>-acetylmannosamine or sialyllactose to these mice prevents and even reverses muscle deterioration. Surprisingly, sialylactose supplements are most effective. We still know relatively little about how each of these sugars are imported into various cells or preferentially used in glycan synthesis (<a href="/books/n/glyco3/ch15/?report=reader">Chapter 15</a>).</p></div></div><div id="Ch45_s5"><h2 id="_Ch45_s5_">DEFECTS IN O-GalNAc GLYCANS</h2><p>A defect in O-GalNAc synthesis by a particular polypeptide GalNAc-transferase (GALNT3) causes familial tumoral calcinosis. This severe autosomal-recessive metabolic disorder shows phosphatemia and massive calcium deposits in the skin and subcutaneous tissues. Mutations in the O-glycosylated fibroblast growth factor 23 (FGF23) also cause phosphatemia, suggesting that <i>GALNT3</i> modifies FGF23. The rare autoimmune disease, Tn syndrome, is caused by somatic mutations in the X-linked gene <i>C1GALT1C1</i>, which encodes a highly specific chaperone COSMC required for the proper folding and normal activity of the β1-3galactosyltransferase C1GALT1 needed for synthesis of core 1 and 2 O-glycans (<a href="/books/n/glyco3/ch10/?report=reader">Chapters 10</a> and <a href="/books/n/glyco3/ch46/?report=reader">46</a>).</p></div><div id="Ch45_s6"><h2 id="_Ch45_s6_">DEFECTS IN PROTEOGLYCAN SYNTHESIS</h2><p>Proteoglycans and their GAG chains are critical components in extracellular matrices. For a discussion of their biosynthesis, core proteins, and function, see <a href="/books/n/glyco3/ch17/?report=reader">Chapter 17</a>.</p><div id="Ch45_s6a"><h3>Ehlers–Danlos Syndrome (Progeroid Type)</h3><p>Ehlers–Danlos syndrome (progeroid type) is a connective tissue disorder characterized by failure to thrive, loose skin, skeletal abnormalities, hypotonia, and hypermobile joints, together with delayed motor development and delayed speech. The molecular basis of the disorder is reduced synthesis of the core region of GAGs initiated by Xyl. Galactosyltransferase I (B4GALT7) the enzyme that adds Gal to Xyl-Ser is mutated in this disease. The activity of galactosyltransferase II (B3GALT6), the enzyme responsible for adding the second Gal to the core of a GAG, may also be reduced. One possible explanation for the dual effect is that the primary mutation affects the formation or stability of a biosynthetic complex involving several GAG biosynthetic enzymes.</p></div><div id="Ch45_s6b"><h3>Congenital Exostosis</h3><p>Defects in the formation of heparan sulfate (HS) cause hereditary multiple exocytosis (HME), an autosomal-dominant disease with a prevalence of about 1:50,000 (<a class="figpopup" href="/books/NBK453041/table/CH45TB1/?report=objectonly" target="object" rid-figpopup="figCH45TB1" rid-ob="figobCH45TB1">Table 45.1</a>). It is caused by mutations in two genes <i>EXT1</i> and <i>EXT2</i>, which are involved in HS synthesis. HME patients have bony outgrowths, usually at the growth plates of the long bones. Normally, the growth plate contains chondrocytes in various stages of development, which are enmeshed in an ordered matrix composed of collagen and chondroitin sulfate (CS). In HME, however, the outgrowths are often capped by disorganized cartilagenous masses with chrondrocytes in different stages of development. About 1%–2% of patients also develop osteosarcoma. HME mutations occur in <i>EXT1</i> (60%–70%) and <i>EXT2</i> (30%–40%). The encoded proteins may form a complex in the Golgi and both are required for polymerizing <i>N</i>-acetylglucosamine (GlcNAc)α1-4 and GlcAβ1-3 into HS. However, the partial loss of one allele of either gene appears sufficient to cause HME. This means that haploinsufficiency decreases the amount of HS and that EXT activity is rate limiting for HS biosynthesis. This is unusual because most glycan biosynthetic enzymes are in substantial excess.</p><p>The mechanism of HME pathology is likely rooted in a disruption of the normal distribution of HS-binding growth factors, which include fibroblast growth factor (FGF) and morphogens such as hedgehog, Wnt, and members of the transforming growth factor β (TGF-β) family. The loss of HS disrupts these pathways in Drosophila. Mice that are null for either <i>Ext</i> gene are embryonic lethal and fail to gastrulate; however, <i>Ext</i> heterozygous animals are viable, and do not develop exostoses on the long bones, in contrast to patients with HME. However, mice with chondrocyte-specific somatic mutations in <i>Ext1</i> cause a loss of heterzygosity and develop exostoses and growth abnormalities in the growth plates of those bones. HS is required to establish and maintain the perichondrium phenotype, and it also restrains prochondrogenic signaling proteins including bone morphogenetic proteins (BMPs) that normally restrict chondrogenesis. Without HS, chondrogenesis increases in localized areas of actively growing cells.</p></div><div id="Ch45_s6c"><h3>Achondrogenesis, Diastrophic Dystrophy, and Atelosteogenesis</h3><p>Three autosomal-recessive disorders, diastrophic dystrophy (DTD), atelosteogenesis type II (AOII), and achondrogenesis type IB (ACG-IB) result from defective cartilage proteoglycan sulfation. These forms of osteochondrodysplasia have various outcomes. AOII and ACG-IB are perinatal lethal because of respiratory insufficiency, whereas DTD patients develop symptoms only in cartilage and bone, including cleft palate, clubfeet, and other skeletal abnormalities. Those DTD patients surviving infancy often live a nearly normal life span. All of these disorders result from different mutations in the DTD gene (<i>SLC26A2</i>), which encodes a plasma membrane sulfate transporter. Unlike monosaccharides, sulfate released from degraded macromolecules in the lysosome is not salvaged well. The heavy demand for sulfate in bone and cartilage proteoglycan synthesis probably explains why the symptoms are most evident in these locations. Defects in the UDP-GlcA/UDP-<i>N</i>-acetylgalactosamine (GalNAc) Golgi transporter (SLC35D1) cause Schneckenbecken dysplasia. Patients have bone abnormalities similar to those seen in other chrondrodysplasias, and a mouse model of the disease shows similar features.</p></div><div id="Ch45_s6d"><h3>Macular Corneal Dystrophy</h3><p>Keratan sulfate I (KS-I) in the cornea is an N-linked oligosaccharide with poly-<i>N</i>-acetyllactosamine repeats (Galβ1-4GlcNAcβ1-3) variably sulfated at the 6-positions. Macular corneal dystrophy (MCD), an autosomal-recessive disease, causes the cornea to become opaque and corneal lesions to develop. Two types of MCD have been described. MCD I appears to be due to a deficiency in sulfating the repeating units. Both Gal and GlcNAc are sulfated in KS; sulfation of Gal and GalNAc in CS are also affected in MCD patients.</p></div></div><div id="Ch45_s7"><h2 id="_Ch45_s7_">DEFECTS IN GPI-ANCHORED PROTEINS</h2><p>Complete deletion of the GPI pathway in mice causes embryonic lethality. This is not surprising because more than 150 membrane proteins require a GPI anchor for cell surface expression (<a href="/books/n/glyco3/ch12/?report=reader">Chapter 12</a>). Hypomorphic mutations in multiple genes in the pathway lead to a partial reduction in GPI-anchored proteins. These include <i>PIGA</i>, <i>PIGQ</i>, <i>PIGY</i>, <i>PIGC</i>, <i>PIGP</i>, <i>PIGL</i>, <i>PIGW</i>, <i>PIGM</i>, <i>PIGV</i>, and <i>PIGO</i> in anchor assembly (<a class="figpopup" href="/books/NBK453041/table/CH45TB1/?report=objectonly" target="object" rid-figpopup="figCH45TB1" rid-ob="figobCH45TB1">Table 45.1</a>), and <i>PIGT</i> in the transfer of the glycan to proteins. Defects in side-chain modifications (<i>PIGN</i> and <i>PIGG</i>) and maturation of GPI following attachment to proteins (<i>PGAP1</i>, <i>PGAP2</i>, and <i>PGAP3</i>) also cause inherited GPI deficiency but not embryonic death. GPI deficiency has immense and variable consequences including neurologic symptoms, particularly developmental delay/intellectual disability and seizures, epileptic encephalopathy, progressive cerebral and/or cerebellar atrophy, hypotonia, cortical visual impairment, sensorineural deafness, and Hirschsprung disease. Nonneurologic phenotypes include brachytelephalangy, anorectal anomaly, renal abnormality, cleft palate, heart defect, and characteristic facial features such as hypertelorism, broad nasal bridge, and tented mouth. Other symptoms such as ichthyosis, iron deposition, hepatosplenomegaly, diaphragmatic hernia, and hepatic and/or portal vein thrombosis were reported in small fractions of the affected individuals. It is not easy to causally relate specific symptoms to deficiency of particular GPI-anchored protein except for few instances. Deficiency of tissue-nonspecific alkaline phosphatase (TNALP) accounts for seizures in some of the patients. Death within a year after birth due to aspiration or status epilepticus is not rare among severely affected individuals with GPI deficiency, whereas mildly affected individuals live with GPI deficiency.</p></div><div id="Ch45_s8"><h2 id="_Ch45_s8_">DEFECTS IN GLYCOSPHINGOLIPID (GSL) SYNTHESIS</h2><p>Only three disorders in GSL synthesis are known in humans. Mutations in <i>ST3GAL5</i> cause autosomal-recessive Amish infantile epilepsy syndrome and also “salt-and-pepper syndrome.” This gene encodes a sialyltransferase required for the synthesis of the ganglioside GM3 (Siaα2-3Galβ1-4Glc-ceramide) from lactosylceramide (Galβ1-4Glc-ceramide). GM3 is also a precursor for some more complex gangliosides. The patients' plasma glycosphingolipids (GSLs) are nonsialylated. In contrast to the human form of the disease, mice that lack GM3 do not have seizures or a shortened life span. However, mouse strains that are null for the sialyltransferase and an N-acetylgalactosaminyltransferase that is required for making other complex gangliosides, do develop seizures, suggesting that it is the absence of these more complex gangliosides that may be the underlying problem (<a href="/books/n/glyco3/ch11/?report=reader">Chapter 11</a>). Mutations in <i>B4GALNT1</i> (also known as GM2/GD2 synthase) cause hereditary spastic paraplegia subtype 26. These patients have developmental delays and varying cognitive impairments with early-onset progressive spasticity owing to axonal degeneration. Cerebellar ataxia, peripheral neuropathy, cortical atrophy, and white-matter hyperintensities were also consistent across the disorder. A <i>B4galnt1</i><sup>−/−</sup> mouse recapitulates several of the neurological characteristics of SPG26, most prominently the progressive gait disorder</p><p>ST3GAL3 makes more complex gangliosides as well as N- and O-glycans. It is required for the development of high cognitive functions and is mutated in some individuals with West syndrome. An <i>St3gal3</i><sup>−/−</sup> mouse model also exists, but these mice appear to have no overt neurological phenotype. GSL disorders are difficult to identify biochemically because no convenient biomarkers exist. Next-generation sequencing will reveal new candidates.</p><div id="Ch45_s8a"><h3>A Deglycosylation Disorder</h3><p>Early on, it was assumed that glycosylation disorders would result from defects in glycan biosynthetic enzymes, but that perspective has changed. Discovery of defects in Golgi organization and homeostasis, in ER chaperones such as COSMC or EDEM, and in ER quality control have broadened the perspective. A new defect in the ER-associated degradation (ERAD) continuum (<a href="/books/n/glyco3/ch39/?report=reader">Chapter 39</a>) is caused by defects in NGLY1, an enzyme that cleaves N-glycans from misfolded glycoproteins transported into the cytoplasm before their proteasomal degradation (<a class="figpopup" href="/books/NBK453041/table/CH45TB1/?report=objectonly" target="object" rid-figpopup="figCH45TB1" rid-ob="figobCH45TB1">Table 45.1</a>). The defect does not appear to induce the ERAD pathway, accumulate undegraded glycoproteins in vesicles, or trigger autophagy. It is unclear how the defect causes symptoms such as developmental delay, movement disorder, seizures, and a curious lack of tear production, but their clinical similarity to other CDGs emphasizes that glycosylation defects cannot simply be divided into “synthesis” or “degradation.”</p></div></div><div id="Ch45_s9"><h2 id="_Ch45_s9_">PHENOTYPES, MULTIPLE ALLELES, AND GENETIC BACKGROUND</h2><p>Phenotypic expression of the same mutation can have highly variable impact, even among affected siblings. Explanations based on residual activity for these “simple Mendelian disorders” are neither simple nor generally satisfying. It is often attributed to “genetic background.” A knockout mutation may be lethal in one highly inbred mouse strain, but not in another because compensatory pathways may exist. Dietary and environmental impacts are substantial as seen in MPI-CDG patients with and without oral mannose therapy. Multiple simultaneous or sequential environmental insults may impinge on borderline genetic insufficiencies to produce overt disease.</p></div><div id="ack42"><h2 id="_ack42_">ACKNOWLEDGMENTS</h2><p>The authors acknowledge contribution of Bobby G. Ng and appreciate helpful comments and suggestions from Aime Lopez Aguilar, Kekoa Taparra, Krithika Vaidyanathan, and Shweta Varshney.</p></div><div id="rl45"><h2 id="_rl45_">FURTHER READING</h2><ul class="simple-list"><li class="half_rhythm"><p><div class="bk_ref" id="CH45C1">Dobson CM, Hempel SJ, Stalnaker SH, Stuart R, Wells L. 2013. O-Mannosylation and human disease. Cell Mol Life Sci
|
|
70:
|
|
2849–2857. [<a href="/pmc/articles/PMC3984002/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3984002</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23115008" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23115008</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="CH45C2">Huegel J, Sgariglia F, Enomoto-Iwamoto M, Koyama E, Dormans JP, Pacifici M. 2013. Heparan sulfate in skeletal development, growth, and pathology: The case of hereditary multiple exostoses. Dev Dyn
|
|
242:
|
|
1021–1032. [<a href="/pmc/articles/PMC4007065/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4007065</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23821404" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23821404</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="CH45C3">Jaeken J. 2013. Congenital disorders of glycosylation. Handb Clin Neurol
|
|
113:
|
|
1737–1743. [<a href="https://pubmed.ncbi.nlm.nih.gov/23622397" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23622397</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="CH45C4">Rosnoblet C, Peanne R, Legrand D, Foulquier F. 2013. Glycosylation disorders of membrane trafficking. Glycoconj J
|
|
30:
|
|
23–31. [<a href="https://pubmed.ncbi.nlm.nih.gov/22584409" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22584409</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="CH45C5">Kinoshita T. 2014. Biosynthesis and deficiencies of glycosylphosphatidylinositol. Proc Jpn Acad Ser B Phys Biol Sci
|
|
90:
|
|
130–143. [<a href="/pmc/articles/PMC4055706/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4055706</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24727937" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24727937</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="CH45C6">Freeze HH, Eklund EA, Ng BG, Patterson MC. 2015. Neurological aspects of human glycosylation disorders. Annu Rev Neurosci
|
|
38:
|
|
105–125. [<a href="/pmc/articles/PMC4809143/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4809143</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25840006" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25840006</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="CH45C7">Hennet T, Cabalzar J. 2015. Congenital disorders of glycosylation: A concise chart of glycocalyx dysfunction. Trends Biochem Sci
|
|
40:
|
|
377–384. [<a href="https://pubmed.ncbi.nlm.nih.gov/25840516" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25840516</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="CH45C8">Maeda N. 2015. Proteoglycans and neuronal migration in the cerebral cortex during development and disease. Front Neurosci
|
|
9:
|
|
98. [<a href="/pmc/articles/PMC4369650/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4369650</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25852466" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25852466</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="CH45C9">Nishino I, Carrillo-Carrasco N, Argov Z. 2015. GNE myopathy: Current update and future therapy. J Neurol Neurosurg Psychiatry
|
|
86:
|
|
385–392. [<a href="/pmc/articles/PMC4394625/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4394625</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25002140" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25002140</span></a>]</div></p></li></ul></div><div style="display:none"><div id="figch9f3"><img alt="Image ch9f03" src-large="/books/n/glyco3/ch9/bin/ch9f03.jpg" /></div><div id="figch9f4"><img alt="Image ch9f04" src-large="/books/n/glyco3/ch9/bin/ch9f04.jpg" /></div></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK453041_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><p class="contrib-group"><h4>Authors</h4><span itemprop="author">Hudson H. Freeze</span>, <span itemprop="author">Harry Schachter</span>, and <span itemprop="author">Taroh Kinoshita</span>.</p><h3>Publication History</h3><p class="small">Published online: 2017.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> 2015-2017 by The Consortium of Glycobiology Editors, La Jolla, California. All rights reserved.<p class="small">PDF files are not available for download.</p></div></div><h3>Publisher</h3><p><a href="http://www.cshlpress.com/default.tpl?action=full&cart=12210755385880789&--eqskudatarq=666" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">Cold Spring Harbor Laboratory Press</a>, Cold Spring Harbor (NY)</p><h3>NLM Citation</h3><p>Freeze HH, Schachter H, Kinoshita T. Genetic Disorders of Glycosylation. 2017. In: Varki A, Cummings RD, Esko JD, et al., editors. Essentials of Glycobiology [Internet]. 3rd edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2015-2017. Chapter 45.<span class="bk_cite_avail"></span> doi: 10.1101/glycobiology.3e.045</p></div><div class="small-screen-prev"><a href="/books/n/glyco3/ch44/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/glyco3/ch46/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="fig" id="figobch45f1"><div id="ch45.f1" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK453041/bin/ch45f01.jpg" alt="FIGURE 45.1.. Glycosylation-related disorders." /></div><h3><span class="label">FIGURE 45.1.</span></h3><div class="caption"><p>Glycosylation-related disorders. The graph shows the cumulative number of human glycosylation disorders in various biosynthetic pathways and the year of their identification. In most cases, the year indicates the definitive proof of gene and specific mutations. In early years, discovery was based on compelling biochemical evidence. Now, discovery is often based on genomic DNA sequencing. In 2013 alone, a new genetically proven glycosylation disorder was reported, on average, every 2 weeks.</p></div><p><a href="/books/NBK453041/bin/ch45f01.pptx">Download Teaching Slide</a><span class="small"> (PPTX, 2.1M)</span></p></div></article><article data-type="table-wrap" id="figobCH45TB1"><div id="CH45TB1" class="table"><h3><span class="label">TABLE 45.1.</span></h3><div class="caption"><p>Selected genetic defects of glycans in humans</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK453041/table/CH45TB1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__CH45TB1_lrgtbl__"><table class="no_bottom_margin"><colgroup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xi="http://www.w3.org/2001/XInclude" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:pmc="http://www.pubmedcentral.gov/pmc" xmlns:xlink="http://www.w3.org/1999/xlink" span="1"><col align="left" span="1" /><col align="left" span="1" /><col align="left" span="1" /><col align="left" span="1" /><col align="left" span="1" /><col align="left" span="1" /><col align="left" span="1" /></colgroup><thead><tr><th id="hd_h_CH45TB1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Disorder</th><th id="hd_h_CH45TB1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gene</th><th id="hd_h_CH45TB1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Function</th><th id="hd_h_CH45TB1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Disorder OMIM</th><th id="hd_h_CH45TB1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gene OMIM</th><th id="hd_h_CH45TB1_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Main Clinical Features</th><th id="hd_h_CH45TB1_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pathway Affected</th></tr></thead><tbody><tr><td headers="hd_h_CH45TB1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">ALG1–CDG</td><td headers="hd_h_CH45TB1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<i>ALG1</i>
|
|
</td><td headers="hd_h_CH45TB1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">β1-4 mannosyltransferase</td><td headers="hd_h_CH45TB1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">608540</td><td headers="hd_h_CH45TB1_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">605907</td><td headers="hd_h_CH45TB1_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ID, Hy, Sz, M, infections, early death</td><td headers="hd_h_CH45TB1_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">N-linked pathway</td></tr><tr><td headers="hd_h_CH45TB1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">NGLY1–CDG</td><td headers="hd_h_CH45TB1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<i>NGLY1</i>
|
|
</td><td headers="hd_h_CH45TB1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">N-glycanase-1</td><td headers="hd_h_CH45TB1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">615273</td><td headers="hd_h_CH45TB1_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">610661</td><td headers="hd_h_CH45TB1_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ID, DD, Sz, abnormal liver function, hypolacrima or alacrima</td><td headers="hd_h_CH45TB1_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">N-linked pathway</td></tr><tr><td headers="hd_h_CH45TB1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">PMM2–CDG</td><td headers="hd_h_CH45TB1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<i>PMM2</i>
|
|
</td><td headers="hd_h_CH45TB1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">conversion of Man-6-P to Man-1-P</td><td headers="hd_h_CH45TB1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">212065</td><td headers="hd_h_CH45TB1_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">601785</td><td headers="hd_h_CH45TB1_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ID, Hy, Sz, strabismus, cerebellar hypoplasia, failure to thrive, cardiomyopathy, 20% lethality in the first 5 yr</td><td headers="hd_h_CH45TB1_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">potential to effect multiple pathways</td></tr><tr><td headers="hd_h_CH45TB1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">MPI–CDG</td><td headers="hd_h_CH45TB1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<i>MPI</i>
|
|
</td><td headers="hd_h_CH45TB1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Conversion of Fruct-6-P and Man-6-P</td><td headers="hd_h_CH45TB1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">602579</td><td headers="hd_h_CH45TB1_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">154550</td><td headers="hd_h_CH45TB1_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">hepatic fibrosis, coagulopathy, hypoglycemia, protein-losing enteropathy, vomiting, no neurological symptoms</td><td headers="hd_h_CH45TB1_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">potential to effect multiple pathways</td></tr><tr><td headers="hd_h_CH45TB1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">SRD5A3–CDG</td><td headers="hd_h_CH45TB1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<i>SRD5A3</i>
|
|
</td><td headers="hd_h_CH45TB1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">polyprenol reductase</td><td headers="hd_h_CH45TB1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">612379</td><td headers="hd_h_CH45TB1_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">611715</td><td headers="hd_h_CH45TB1_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ID, Hy, eye, and brain malformations, nystagmus, hepatic dysfunction, coagulopathy, ichthyosis</td><td headers="hd_h_CH45TB1_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">potential to effect multiple pathways</td></tr><tr><td headers="hd_h_CH45TB1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">COG7–CDG</td><td headers="hd_h_CH45TB1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<i>COG7</i>
|
|
</td><td headers="hd_h_CH45TB1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Golgi-to-ER retrograde transport</td><td headers="hd_h_CH45TB1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">608779</td><td headers="hd_h_CH45TB1_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">606978</td><td headers="hd_h_CH45TB1_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Hy, M, growth retardation, adducted thumbs, failure to thrive, cardiac anomalies, wrinkled skin, early death</td><td headers="hd_h_CH45TB1_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">potential to effect multiple pathways</td></tr><tr><td headers="hd_h_CH45TB1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">CHIME syndrome Hyperphosphatasia mental retardation syndrome</td><td headers="hd_h_CH45TB1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<i>PIGL</i>
|
|
</td><td headers="hd_h_CH45TB1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">GlcNAc-PI de-N-acetylase</td><td headers="hd_h_CH45TB1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">280000 239300</td><td headers="hd_h_CH45TB1_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">605947 605947</td><td headers="hd_h_CH45TB1_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ID, colobomas, heart defect, early-onset ichthyosiform dermatosis, ear anomalies (conductive hearing loss) hyperphosphatasia with mental retardation syndrome</td><td headers="hd_h_CH45TB1_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">GPI-anchor pathway</td></tr><tr><td headers="hd_h_CH45TB1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Walker–Warburg syndrome (MDDGA1, B1, C1)</td><td headers="hd_h_CH45TB1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<i>POMT1</i>
|
|
</td><td headers="hd_h_CH45TB1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">O-mannosyltransferase</td><td headers="hd_h_CH45TB1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">236670 613155 609308</td><td headers="hd_h_CH45TB1_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">607423</td><td headers="hd_h_CH45TB1_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Walker–Warburg syndrome, brain malformations, various eye malformations, elevated serum CK</td><td headers="hd_h_CH45TB1_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">dystroglycanopathy</td></tr><tr><td headers="hd_h_CH45TB1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">GNE myopathy</td><td headers="hd_h_CH45TB1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<i>GNE</i>
|
|
</td><td headers="hd_h_CH45TB1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">UDP-GlcNAc-2-epimerase/MaNAc kinase</td><td headers="hd_h_CH45TB1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">605820 269921</td><td headers="hd_h_CH45TB1_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">603824</td><td headers="hd_h_CH45TB1_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">proximal and distal muscle weakness, wasting of the upper and lower limbs, sparing of the quadriceps</td><td headers="hd_h_CH45TB1_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">dystroglycanopathy</td></tr><tr><td headers="hd_h_CH45TB1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Hereditary multiple exocytosis</td><td headers="hd_h_CH45TB1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<i>EXT1</i>
|
|
</td><td headers="hd_h_CH45TB1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">glucuronyltransferase/GlcNAc transferase</td><td headers="hd_h_CH45TB1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">133700</td><td headers="hd_h_CH45TB1_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">608177</td><td headers="hd_h_CH45TB1_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">multiple exocytosis of the bone</td><td headers="hd_h_CH45TB1_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">glycosaminoglycan</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CDG, congenital disorders of glycosylation; OMIM, Online Mendelian Inheritance in Man database; ID, intellectual disability; Sz, seizures; Hy, hypotonia; M, microcephaly; DD, developmental delay; CK, creatine kinase.</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobch45f2"><div id="ch45.f2" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK453041/bin/ch45f02.jpg" alt="FIGURE 45.2.. Congenital disorders of glycosylation in the N-glycosylation pathway." /></div><h3><span class="label">FIGURE 45.2.</span></h3><div class="caption"><p>Congenital disorders of glycosylation in the N-glycosylation pathway. The figure shows individual steps in lipid-linked oligosaccharide (LLO) biosynthesis, glycan transfer to protein, and N-glycan processing similar to <a href="/books/n/glyco3/ch9/?report=reader#ch9.f3">Figure 9.3</a> and <a href="/books/n/glyco3/ch9/?report=reader#ch9.f4">Figure 9.4</a>. The shuttling of the glycosylation machinery between the ER and Golgi is organized and regulated by cytoplasmic complexes including the conserved oligomeric Golgi (COG) complex. <i>Red</i> gene names indicate congenital disorders of glycosylation (CDG).</p></div><p><a href="/books/NBK453041/bin/ch45f02.pptx">Download Teaching Slide</a><span class="small"> (PPTX, 2.3M)</span></p></div></article><article data-type="fig" id="figobch45f3"><div id="ch45.f3" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK453041/bin/ch45f03.jpg" alt="FIGURE 45.3.. UDP-Gal synthesis and galactosemia." /></div><h3><span class="label">FIGURE 45.3.</span></h3><div class="caption"><p>UDP-Gal synthesis and galactosemia. The most common form of galactosemia is due to a deficiency of galactose-1-phosphate uridyltransferase (GALT). This enzyme normally uses Gal-1-P derived from dietary Gal. In the absence of GALT, Gal-1-P accumulates, along with excessive Gal and its oxidative and reductive products galactitol and galactonate (not shown). UDP-Gal synthesis may also be impaired in the absence of GALT, but not completely because UDP-Gal-4′-epimerase (GALE) can form UDP-Gal from UDP-Glc and can supply the donor to galactosyltransferases required for normal glycoconjugate biosynthesis.</p></div><p><a href="/books/NBK453041/bin/ch45f03.pptx">Download Teaching Slide</a><span class="small"> (PPTX, 1.7M)</span></p></div></article><article data-type="fig" id="figobch45f4"><div id="ch45.f4" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK453041/bin/ch45f04.jpg" alt="FIGURE 45.4.. O-Man glycan biosynthetic pathway." /></div><h3><span class="label">FIGURE 45.4.</span></h3><div class="caption"><p>O-Man glycan biosynthetic pathway. The biosynthetic pathways of representative O-Man glycans are shown. Genes that cause a disorder are indicated in red. Three main groups are identified: core M1–M3. All O-Man glycans are initiated on either a serine (S) or a threonine (T) in the acceptor protein using two enzymes protein-O-mannosyltransferase 1 and 2 (POMT1/2) and Dol-P-Man donor. Several genes in the biosynthesis of Dol-P-Man (<i>GMPPB, DPM1</i>–<i>3</i>) are deficient in some patients with dystroglycanopathy, whereas others (<i>DOLK, DPM1,</i> and <i>PMM2</i>) cause a more generalized congenital disorders of glycosylation (CDG). Mannose receives either GlcNAcβ1-2- to form core M1 or β1-4GlcNAc to form core M3. Mutations in both genes (<i>POMGNT1</i> and <i>POMGNT2</i>) can cause a dystroglycanopathy. Core M2 can be formed if a branching β1-6GlcNAc is added. Core M1 and M2 are elongated by Gal and may terminate with Fuc, Sia, and GlcA with optional sulfation. None of the genes responsible for adding the terminal sugars have been associated with dystroglycanopathies. After the addition of the β1-4GlcNAc, core M3 is elongated with GalNAc, and then the Man is 6-O-phosphorylated via a specific kinase (POMK, also known as SGK196). With help of POMGNT1, FKTN and FKRP can act to add two ribitol-5-phosphate units to the GalNAc residue that is then extended with a single Xyl and GlcA by TMEM5 and B4GAT1, respectively. Ribitol-5-phosphate used by FKTN and FKRP is synthesized from CDP-ribitol by ISPD. Mutations in these genes (<i>B3GALNT2</i>, <i>POMK</i>, <i>FKTN</i>, <i>FKRP</i>, <i>ISPD, TMEM5,</i> and <i>B4Gat1</i>) can cause a dystroglycanopathy. The last defined step in core M3 biosynthesis is using this Xyl-GlcA primer for the stepwise addition of Xyl and GlcA to form a GAG-like repeating disaccharide termed matriglycan. This is catalyzed by the enzyme encoded by <i>LARGE</i> (or its homolog <i>GYLTL1B</i>) with dual glycosyltransferase activities. Matriglycan binds laminin to α-DG and its reduction or loss is believed to be the cause of most of the dystroglycanopathies (<i>POMGNT1</i> mutations being the exception).</p></div><p><a href="/books/NBK453041/bin/ch45f04.pptx">Download Teaching Slide</a><span class="small"> (PPTX, 2.1M)</span></p></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|